This Medocef drug is used for the combined and monotherapeutic treatment of diseases caused by pathogens that are sensitive to the main active ingredient – cefoperazone.
active substance: cefoperazone;
1 vial contains cefoperazone sodium equivalent to cefoperazone 1 g
Powder for solution for injection.
Medocef is an antibacterial drug for systemic use, based on the active ingredient cefoperazone, which is a third generation cephalosporin.
It is active in microorganisms that are relatively sensitive to it, which are in the stage of active multiplication, due to the property of inhibiting the biosynthesis of mucopeptide of cell membranes.
This Medocef drug is used for the combined and monotherapeutic treatment of diseases caused by pathogens that are sensitive to the main active ingredient – cefoperazone. In particular, it is prescribed for the treatment of infections:
- lower and upper respiratory tract;
- urinary tract (pyelonephritis, kidney abscess, cystitis, apostematous nephritis);
- skin, soft tissues (abscesses, phlegmon, pyoinflammatory diseases of pararectal tissue, gangrene of the extremities);
- bones and joints (bacterial arthritis, osteomyelitis);
- genitourinary system in men (prostatitis, orchitis, epididymitis.
scarlet pelvis (endometritis, gonorrhea, other genital infections)
abdominal cavity (peritonitis, cholecystitis, cholangitis).
It is also prescribed for the treatment of septicemia, meningitis.
It can be used to prevent the development of postoperative complications during abdominal, gynecological, cardiovascular and orthopedic operations.
Do not use for allergic reactions to drugs of the cephalosporin group.
It is undesirable to consume alcoholic beverages during treatment with cephalosporins. Even after 5 days of the last administration of cefoperazone after drinking alcohol, the patients experienced a disulfiram-like reaction, which was characterized by hot flashes, sweating, headaches and tachycardia.
You should also avoid preparations containing ethanol.
Cefoperazone can be used effectively in infants. Large-scale studies involving premature infants and newborns have not been performed. Therefore, before prescribing cefoperazone to premature infants and newborns, the potential benefits and possible risks of therapy with this drug should be carefully weighed.
In neonates with nuclear jaundice, cefoperazone does not displace bilirubin from its plasma protein binding sites.
Application during pregnancy and lactation
There is no evidence that the use of this drug is absolutely harmless to pregnant women and the fetus. Therefore, it is permissible to prescribe it when carrying a child only when the possible benefits of using the drug are higher than the possible harm.
During breastfeeding, the drug enters breast milk in some amount. As a result, lactation should be suspended during the treatment process.
Method of administration and dosage
Medocef is given as an intravenous or intramuscular injection, twice a day, 12 hours apart, in a single dose of 2-4 grams.
In severe cases, the dosage can be increased to 8 grams, also with a difference of 12 hours.
The duration of the course of treatment is determined by the attending physician, depending on the severity of the disease.
For uncomplicated gonococcal urethritis, a single administration of 500 mg of this drug is recommended. In this case, the injection is intramuscular. It is produced in the front of the thigh or deep in the gluteus maximus muscle.
In hepatic and renal failure, the dosage can be reduced to 4 grams per day.
Simultaneous treatment with aminlycosides should be carried out with constant monitoring of kidney function.
The preparation of the solution for injection is carried out by qualified medical personnel in accordance with the requirements specified in the special medical literature.
In case of overdose, an increase in side effects can be expected, especially those affecting the central nervous system. Convulsions may occur.
In this case, gastric lavage, intake of sorbents, and symptomatic therapy are recommended.
Hemodialysis and symptom management are recommended.
Side effects are usually mild and do not interfere with continuing treatment. Most often they appear as:
- nausea, vomiting, pseudomembranous colitis, drug fever, diarrhea (diarrhea);
- skin rash, urticaria;
- pain and / or phlebitis at the injection site, muscle twitching;
- neutropenia, eosinophilia, thrombocytopenia, hypoprothrombinemia, drug-induced fever, decreased hemoglobin.
There was also an increase in blood pressure, the occurrence of hematuria, vasculitis.
Storage conditions and periods
The shelf life of capsules is up to 2 years at a temperature not exceeding 25 ° C.